Global Influenza Vaccines Market, Persons Vaccinated, Brand Analysis, Size, Share, Growth, Trends, Major Deals - Forecast to 2024

Wednesday, August 8, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, August 8, 2018 /PRNewswire/ -- The global influenza vaccines market is anticipated to exceed US$

5.8 Billion mark by 2024, and is presenting ample opportunities to the industry's players. Influenza viruses are considered as a major cause of morbidity and mortality worldwide. The vast population base together with significantly low vaccination
coverage in emerging markets, introduction of new vaccines, rising government support for immunization and growing awareness of the value of influenza vaccine in preventing disease are the prominent factors that will drive the influenza vaccines market. However, shortage of vaccine supply due to genetic assortment of the viral strains is surging the need for updating vaccines each year by the manufacturers. This is a major factor restraining market growth.Download the full report: https://www.reportbuyer.com/product/5473810 Global Influenza Vaccines Market – Regional Analysis• Geographically, North America is the largest market for influenza vaccines capturing over 48% market share in 2017.• Asia is the second largest market for influenza vaccines.• Europe is the third largest market for influenza vaccines, followed by Latin America.• Australasia accounted for least share of the influenza vaccines market in 2017.Global Influenza Vaccines Market – Country Wise Analysis• On the basis of country, United States captures majority of the influenza vaccines market.• Japan is the second largest market for influenza vaccines.• China, Brazil and India are the third, fourth and fifth leading market for influenza vaccines respectively.• Canada, Germany, France, UK, Italy, Spain and South Korea are the other leading market for influenza vaccines.Global Influenza Vaccines Market – Brands Analysis• In the influenza vaccines brand sales segment, Sanofi's Fluzone holds the maximum share of the market being followed by Fluvirin/Flucelvax.• In May 2016, the cell-based Flucelvax quadrivalent shot was approved by the FDA.• GSK's Fluarix/FluLaval accounts for the third highest share of the influenza vaccines market.• Fluad is the first and only adjuvanted seasonal influenza vaccine in the US for adults aged 65 and older.• Flublok has captured least share of the influenza vaccines market.• In October 2016, Protein Sciences received approval from the FDA for the quadrivalent version of Flublok vaccine.• On August 28, 2017 - Sanofi announced that it has completed the acquisition of Protein Sciences.• In February 2018, SK Chemicals Co. signed a US$ 155 Million deal to license cell culture technology to Sanofi Pasteur Inc. for development of a universal influenza vaccine.This is the 4th edition report on influenza vaccines market by iGATE Research. The report titled "Global Influenza Vaccines Market, Persons Vaccinated, Brand Analysis, Size, Share, Growth, Trends, Major Deals - Forecast to 2024" provides a comprehensive assessment of the fast-evolving, high-growth influenza vaccines market landscape.This 224 Page report with 139 Figures and 12 Tables has been analyzed from 5 viewpoints:1. Influenza Vaccines Market, Persons Vaccinated and Forecast - By Region (2011 - 2024)2. Influenza Vaccines Market, Persons Vaccinated and Forecast - Country Wise Distribution (2011 - 2024)3. Global - Influenza Vaccines Brand Sales and Forecast to 20244. Global Influenza Vaccines Market - Major Deals5. Global Influenza Vaccines Market - Driving Factors and ChallengesInfluenza Vaccines Market, Persons Vaccinated and Forecast - By Region1. North America2. Latin America3. Europe4. Asia5. AustralasiaInfluenza Vaccines Market, Persons Vaccinated and Forecast - Country Wise Distribution (25 Countries Covered)1. United States2. Canada3. Brazil4. Mexico5. Germany6. France7. Italy8. Spain9. United Kingdom10. Netherlands11. Ireland12. Denmark13. Luxembourg14. Sweden15. Australia16. New Zealand17. Japan18. China19. India20. South Korea21. Singapore22. Hong Kong23. Malaysia24. Thailand25. IndonesiaInfluenza Vaccines Brand Sales and Forecast - 8 Brands Analyzed1. Fluarix/FluLaval2. Fluzone3. Fluvirin/Flucelvax4. Influvac5. Afluria/Fluvax6. FluMist/Fluenz7. Flublok8. FluadCompanies MentionedGSK, Sanofi Pasteur, Novartis, bioCSL, Protein Sciences, SeqirusDownload the full report: https://www.reportbuyer.com/product/5473810 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com Tel: +1 (718) 213 4904 Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/global-influenza-vaccines-market-persons-vaccinated-brand-analysis-size-share-growth-trends-major-deals---forecast-to-2024-300694051.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store